Trial Profile
A Randomized, Placebo-controlled, Double-blinded Phase 2 Study of Second-line Treatment With OSI-906 in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure of First-line Treatment With Sorafenib.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs Linsitinib (Primary)
- Indications Liver cancer
- Focus Biomarker; Registrational; Therapeutic Use
- Sponsors Astellas Pharma
- 02 Apr 2022 This trial has been completed in Germany (End Date: 4 Nov 2011) according to European Clinical Trials Database record.
- 21 Dec 2011 Actual patient number (23) added as reported by ClinicalTrials.gov.
- 21 Dec 2011 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.